Fig 6.TIF (633.36 kB)

ViscumTT reduces the growth of human Ewing sarcoma xenograft tumors in mice.

Download (633.36 kB)
posted on 02.09.2016, 17:33 by Monika Twardziok, Susann Kleinsimon, Jana Rolff, Sebastian Jäger, Angelika Eggert, Georg Seifert, Catharina I. Delebinski

Established Ewing sarcoma xenograft tumors were intratumorally (i.t.) injected with 40/50/60mg oleanolic acid/kg mouse weight (TT i.t.), 0.75/1.25/1.75μg mistletoe lectin /kg mouse weight (viscum i.t.) or a combination thereof (viscumTT i.t.) every 2 to 3 days in increasing concentrations. Each concentration was administered twice within 2–3 days. One treatment group received viscumTT intravenously (i.v.), and one positive control group was once intravenously (i.v.) treated with 4 mg/kg doxorubicin. The negative control group received the solubilizing agent, cyclodextrins (CD), which was injected either intratumorally (CD i.t.) or intravenously (CD i.v.). One-way ANOVA revealed a significant group effect (p = 0.007) and Fisher´s Least Significant Difference test comparing all groups with all groups showed a significant effect between the CD i.t. control group and viscumTT i.t. (p = 0.033), viscum i.t. (p = 0.002) and TT i.t. (p = 0.021) as well as between the CD i.v. control group and viscumTT i.v. (p = 0.014) or the positive control group, doxorubicin i.v. (p = 0.015). Box-and-wisker plots each represent one treatment group including 8 mice (*p < 0.05, **p < 0.005).